Attorney Docket No. **5623-13** PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Wilson et al.**
Application No.: **Not Yet Assigned** Group Art Unit: **Not Yet Assigned**
Filed: **Concurrently Herewith** Examiner: **Not Yet Assigned**
For: ***A_1 ADENOSINE RECEPTOR ANTAGONISTS***

Date: February 17, 2004

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the waiver by the U.S. Patent and Trademark Office of requirements under 37 C.F.R. § 1.98(a)(2)(i) for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP. No fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Kenneth D. Sibley
Registration No. 31,665

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

CERTIFICATE OF EXPRESS MAILING
"Express Mail" mailing label number: EV385144106US
Date of Deposit: February 17, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Lyndsey D. Hall, CP
Certified Paralegal

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Wilson
				Group Art Unit	Not Yet Assigned
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	5623-13

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	1	5,719,279		Kufner-Muhl et al.	02-17-1998
	2	5,786,360		Constance Neely	07-28-1998
	3	2002/0058667		Castelhano et al.	05-16-2002

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office	Number	Kind Code (if known)			

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	4	BELARDINELLI ET AL., *1, 3-Dipropyl-8-[2-(5, 6-Epoxy)Norbomyl]Xanthine, a Potent Specific and Selective A_1 Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT $_1$MF-2 Cells*, The Journal of Pharmacology and Experimental Therapeutics, Vol. **276**, No. 2:1167-1176 (1995)	
	5	BEAUGLEHOLE ET AL., *New Irreversible Adenosine A_1 Antagonists Based on FSCPX*, Bioorganic and Medicinal Chemistry Letters, **12**:3179-3182 (2002)	
	6	BEAUGLEHOLE ET AL., *Fluorosulfonyl-Substituted Xanthines as Selective Irreversible Antagonists for the A_1-Adenosine Receptor*, J. Med. Chem. **43**:4973-4980 (2000)	
	7	SONJA HESS, *Recent Advances in Adenosine Receptor Antagonist Research*, Expert Opinion, Ashley Publications, 1354-3776 (2001)	
	8	JACOBSON ET AL., *Adenosine Receptors: Pharmacology, Structure-Activity Relationships; and Therapeutic Potential*, Journal of Medicinal Chemistry, Vol. **35**, No. 3:407-422 (February 7, 1992)	
	9	KURODA ET AL., *Design, Synthesis and Biological Evaluation of a Novel Series of Potent, Orally Active Adenosine A_1 Receptor Antagonists with High Blood-Brain Barrier Permeability*, Chem. Pharm. Bull., **49**:988-998 (2001)	
	10	NICOT ET AL., *High-Performance Liquid Chromatographic Method for the Determination of Bamifylline and it's Three Metabolites in Human Plasma*, Journal of Chromatography, **277**:239-249 (1983)	
	11	NOVELLINO ET AL., *Design, Synthesis and Biological Evaluation of Novel N-Alkyl-and N-Acyl-(7-subsituted-2-2phenylimidazo[1.2-a] [1,3,5] triaxzin-4-yl] amines (ITAs) as Novel A_1 Adenosine Receptor Antagonists*, J. Med. Chem. **45**:5030-5036 (2002)	
	12	SACCHI ET AL., *Research on Heterocyclic Compounds. Part XXXVI. Imidazo[1,2-a]pyrimidine-2-acetic derivatives: synthesis and anti-inflammatory activity*, Eur. J. Med. Chem., **32**:677-682 (1997)	
	13	SCAMMELLS ET AL., *Substituted 1,3-Dipropylxanthines as Irreversible Antagonists of A_1 Adenosine Receptors*, J. Med. Chem. **37**:2704-2712 (1994)	
	14	VAN MUIJLWIJK-KOEZEN ET AL., *Synthesis and Use of FSCPX, an Irreversible Adenosine A_1 Antagonist, as a 'Receptor Knock-Down' Tool*, Bioorganic & Medicinal Chemistry Letters, **11**:815-818 (2001)	
	15	VAN GALEN ET AL., *A Model for the Antagonist Binding Site on the Adenosine A_1 Receptor, Based on Steric, Electrostatic, and Hydrophobic Properties*, J. Med. Chem., **33**:1708-1713 (1990)	
	16	VAN TILBURG ET AL., *Subsituted 4-Phenyl-2-2(phenylcarboxamido)-1,3-thiazole Derivatives as Antagonists for the Adenosine A_1 Receptor*, Bioorganic & Medicinal Chemistry Letters, **11**:2017-2019 (2001)	
	17	WILSON ET AL., *Lipopolysaccaride Binds to and Activates A_1 Adenosine Receptors on Human Pulmonary Artery Endothelial Cells*, Journal of Endotoxin Research, Vol. **8**, No. **4**:263-271 (2002)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.